Oxurion Extends Convertible Bond Financing Until March 2027
Biopharmaceutical company Oxurion has signed a fourth amendment to its financing agreement with Atlas Special Opportunities II, LLC, extending its convertible bond issuance program. This amendment modifies the terms and duration of the existing financing arrangement.
Extension of Financing Program
The financing program has been extended until March 2, 2027. The convertible bonds issued or to be issued will now have a maturity of 72 months from their respective issuance dates. The subscriber, Atlas Special Opportunities II, LLC, will continue to subscribe to monthly bonds under the same conditions until this new deadline. The new amendment also expands the subscriber's rights by allowing them to assign or transfer the convertible bonds and subscription rights to affiliated entities located outside the United States, without prior consent from the Company.
Conditions for Accessing Financing
The conditions for accessing financing remain governed by market capitalization and liquidity thresholds. A minimum market capitalization of EUR 500,000 over 30 days is required for bond issuance, with the possibility of partial drawdowns if capitalization temporarily drops to EUR 250,000. A transaction volume of at least EUR 1.2 million over 22 consecutive trading days must be achieved, this threshold being reduced to EUR 600,000 for partial draws. The basic monthly issuance remains set at EUR 300,000, with possible increases of EUR 100,000 subject to the subscriber's agreement. The parties noted that approval from the FSMA might be required before implementing this amendment.
